Sofarmex SRL
Sofarmex reported revenue of €30.0m for the 2026 financial year (annual accounts filed with the NBB on 30 Jun 2026).
The score of Sofarmex shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2026
Change 2023 → 2026: Revenue +28 % Equity +6563 % Total assets -21 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Sofarmex's annual accounts
Filed annual accounts
- Year ended 31 Jan 2026filed on 30 Jun 2026
- Year ended 31 Jan 2025filed on 07 Jul 2025
- Year ended 31 Jan 2024filed on 10 Jul 2024
- Year ended 31 Mar 2023filed on 17 Oct 2023
- Year ended 31 Mar 2022filed on 11 Oct 2022
Sofarmex's financial analysis
- Solvency85.9%sector median: 41.4%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Sofarmex
Sofarmex's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0654.747.129
- VAT number
- BE0654747129
- Peppol
- Registered · 0208:0654747129 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 17 May 2016
- Registered office
- 1200 Woluwe-Saint-Lambert
- Latest accounts
- 2026 · filed on 30 Jun 2026
- Activity
- Manufacture of other pharmaceutical products (NACE 21209)
Sofarmex (SRL) has been based in Woluwe-Saint-Lambert since 2016, active in: manufacture of other pharmaceutical products. For 2026, it reports revenue of €30.0m, a net profit of €2.45m and equity of €4.50m. Its solvency stands at 85.9%, above the median of its sector (41.4%).
Companies similar to Sofarmex
Companies in the same business, of comparable size and area, outside its group.
- Mondomed Manufacture of pharmaceutical preparations Hamont-Achel · balance sheet €4.65m
- L - Pharma Manufacture of pharmaceutical preparations Turnhout · balance sheet 10 €
- RTLC Manufacture of pharmaceutical preparations Brussels · balance sheet 107,167 €
- Laboratoria Wolfs Manufacture of pharmaceutical preparations Beveren-Kruibeke-Zwijndrecht · balance sheet €6.74m
- IRE ELiT Manufacture of pharmaceutical preparations Fleurus · balance sheet €19.5m
- KCI Polymedics Manufacture of other chemical products n.e.c. Peer · balance sheet €5.03m
- -Heel Belgium Manufacture of pharmaceutical preparations Ghent · balance sheet €3.17m
- Upjohn Manufacture of pharmaceutical preparations Hoeilaart · balance sheet €12.3m
Frequently asked questions about Sofarmex
What is the revenue of Sofarmex?
According to the 2026 annual accounts filed with the NBB, the revenue of Sofarmex amounts to 30,041,151 €.
What is the VAT number of Sofarmex?
In Belgium, the VAT number is the company number prefixed with BE: BE0654747129 for Sofarmex, if the company is VAT-registered. Its company number (CBE) is 0654.747.129.
Where is the registered office of Sofarmex?
According to the CBE register, the registered office of Sofarmex is in 1200 Woluwe-Saint-Lambert.
What is the equity of Sofarmex?
At the close of the 2026 financial year, the equity of Sofarmex amounts to 4,496,430 €, a solvency of 85.9% of total assets.
Who manages Sofarmex?
The register lists 2 active mandates at Sofarmex. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Sofarmex
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →